Fig. 2
From: The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer
HV-107 affects cell viability in breast cancer cell lines. The results of the trypan blue exclusion assays (A–C) and MTT assays (D–F) evaluating cell viability in MCF10A, MDA-MB-231, and MDA-MB-468 cells treated with HV-107 for 72 h are displayed. The relative cell viability is depicted as a percentage of the control (cells treated with the vehicle only). N = 3. Error bars represent ± SEM; significant differences from control (*) are shown (p < 0.05)